Studies Addressing Rare Neurodegenerative Diseases including ALS

The Food and Drug Administration is seeking to fund research aimed at advancing medical product development for interventions targeting ALS and other rare neurodegenerative diseases in both adult and pediatric populations. The goal is to fill critical knowledge gaps that currently hinder progress in preventing, diagnosing, mitigating, treating, or curing these disorders, with a strong emphasis on generating data that directly informs and accelerates future product development efforts. By supporting these studies, the FDA aims to drive meaningful scientific advances that can lead to tangible therapeutic and diagnostic solutions for patients affected by these conditions. This funding opportunity, titled Studies Addressing Rare Neurodegenerative Diseases including ALS, was posted on August 14, 2024, under the Department of Health and Human Services. It is currently in the forecast stage, with no set-aside type or NAICS code specified. Interested applicants should direct inquiries to Terrin Brown, the designated point of contact, via email at terrin.brown@fda.hhs.gov or by phone at 240-402-7610. Further details and application information are available through the Grants.gov portal using the provided UI link.